News

AMTD's 'The Last Dance' Sets New Milestone in Film History

AMTD's 'The Last Dance' Sets New Milestone in Film History

AMTD Group’s Historic Achievement with 'The Last Dance'

AMTD Group Inc. proudly announces its latest film, 'The Last Dance,' which has made a significant impact in the Hong Kong movie industry. The film has set remarkable milestones, having shattered nine major records in Hong Kong cinema.

Box Office Success

'The Last Dance' has achieved an incredible box office gross of HK$100 million, securing its position as one of the top three highest-grossing local films in the history of Hong Kong. This success not only highlights the film’s appeal locally but also nods to the growing strength of the Hong Kong film industry.

International Acclaim

Beyond Hong Kong, 'The Last Dance' has gained significant recognition internationally, particularly in regions such as Malaysia, the UK, and Singapore. Its reception has been overwhelmingly positive, and plans are underway to release it in additional countries later this year, enhancing its global footprint.

Production and Vision

The film was produced by World Media and Entertainment Group, a subsidiary of AMTD Group, which has a strong commitment to nurturing creative storytelling. Dr. Calvin Choi, the founder of AMTD IDEA Group and AMTD Digital, played a pivotal role as a producer, ensuring the artistic vision of the project came to fruition.

About AMTD Group

AMTD Group operates as a dynamic conglomerate, focusing on a wide array of sectors including media and entertainment, education and training, and hospitality. This diverse portfolio allows the group to leverage its expertise across multiple industries, contributing to innovative solutions that drive growth.

About AMTD IDEA Group

The AMTD IDEA Group (NYSE: AMTD; SGX: HKB) is a global institution providing a digital solutions platform that connects businesses and investors worldwide. Its model encompasses a comprehensive suite of services tailored to meet the evolving needs of its clients throughout various stages of their development. Uniquely positioned, AMTD serves as a conduit between East and West, facilitating cross-border collaboration and investment.

About AMTD Digital Inc.

Headquartered in France, AMTD Digital Inc. (NYSE: HKD) is a comprehensive digital solutions provider. The company specializes in multiple areas, including digital services, content marketing, hospitality, and VIP services. By addressing diverse client needs, AMTD Digital continues to advance its offerings, ensuring relevance in a fast-evolving digital landscape.

Frequently Asked Questions

What is the significance of 'The Last Dance' in Hong Kong cinema?

'The Last Dance' has broken multiple records, establishing itself as a major milestone in local film history, showcasing the strength of contemporary Hong Kong cinema.

Which companies are associated with producing 'The Last Dance'?

The film was produced by World Media and Entertainment Group, under the umbrella of AMTD Group, which has a rich portfolio in media and entertainment.

When can audiences expect to see the film in other countries?

The film is anticipated to be released in more regions later this year, increasing its international presence and viewership.

What are the main sectors AMTD Group operates in?

AMTD Group focuses on media and entertainment, education and training, as well as hospitality, showcasing its extensive reach across various industries.

How can I learn more about AMTD Group's services?

For more information about AMTD Group and its wide range of services, visiting its official website or exploring its digital platforms would be beneficial.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading